Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by EFG Asset Management North America Corp.

EFG Asset Management North America Corp. trimmed its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 40.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 145,629 shares of the biotechnology company's stock after selling 98,791 shares during the quarter. EFG Asset Management North America Corp. owned 0.16% of Rocket Pharmaceuticals worth $1,831,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. SG Americas Securities LLC boosted its stake in shares of Rocket Pharmaceuticals by 796.2% during the fourth quarter. SG Americas Securities LLC now owns 54,921 shares of the biotechnology company's stock valued at $690,000 after purchasing an additional 48,793 shares in the last quarter. Jennison Associates LLC boosted its position in Rocket Pharmaceuticals by 72.6% during the 4th quarter. Jennison Associates LLC now owns 70,304 shares of the biotechnology company's stock valued at $884,000 after acquiring an additional 29,564 shares in the last quarter. Mirador Capital Partners LP increased its holdings in shares of Rocket Pharmaceuticals by 403.9% in the 4th quarter. Mirador Capital Partners LP now owns 84,529 shares of the biotechnology company's stock valued at $1,063,000 after acquiring an additional 67,755 shares during the period. Sovran Advisors LLC purchased a new stake in shares of Rocket Pharmaceuticals during the 4th quarter worth $1,895,000. Finally, Strategic Financial Concepts LLC bought a new stake in Rocket Pharmaceuticals during the fourth quarter valued at about $141,000. Institutional investors own 98.39% of the company's stock.

Remove Ads

Rocket Pharmaceuticals Trading Down 3.7 %

Shares of RCKT traded down $0.29 during trading hours on Friday, hitting $7.59. The stock had a trading volume of 1,094,321 shares, compared to its average volume of 1,043,648. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.05. Rocket Pharmaceuticals, Inc. has a 12-month low of $7.48 and a 12-month high of $26.99. The firm has a market cap of $809.32 million, a P/E ratio of -2.76 and a beta of 1.03. The company's fifty day simple moving average is $9.62 and its 200 day simple moving average is $13.24.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.06. Equities research analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on RCKT. Scotiabank boosted their price target on Rocket Pharmaceuticals from $51.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Monday, March 3rd. Wedbush started coverage on Rocket Pharmaceuticals in a research report on Monday, December 30th. They set an "outperform" rating and a $32.00 price target for the company. The Goldman Sachs Group lowered their target price on shares of Rocket Pharmaceuticals from $29.00 to $15.00 and set a "neutral" rating on the stock in a research note on Monday, March 3rd. Needham & Company LLC lowered their target price on shares of Rocket Pharmaceuticals from $52.00 to $42.00 and set a "buy" rating on the stock in a research note on Friday, February 28th. Finally, Canaccord Genuity Group lowered their target price on shares of Rocket Pharmaceuticals from $39.00 to $36.00 and set a "buy" rating for the company in a research note on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, Rocket Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $43.00.

Rocket Pharmaceuticals Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.